EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Characterization of sulopenem antimicrobial activity using in vitro time-kill kinetics, synergy, post-antibiotic effect, and sub-inhibitory MIC effect methods against Escherichia coli and Klebsiella pneumoniae isolates

Joshua M Maher iD, Michael D Huband iD, Jill M Lindley, Paul R Rhomberg, Steven I Aronin iD, Sailaja Puttagunta, Mariana Castanheira iD

Microbiology Spectrum · 2025

DOI: 10.1128/spectrum.01898-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbiology Spectrum, 2025. Verfasst von Joshua M Maher und 6 weiteren Autor:innen. Beteiligte Einrichtung: Element Iowa City-JMI Laboratories, North Liberty, Iowa, USA. Hauptthemen laut MEDLINE: Klebsiella pneumoniae, Anti-Bacterial Agents, Escherichia coli. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sulopenem is an oral and intravenous penem antibiotic in clinical development for treatment of urinary tract and intra-abdominal infections caused by multidrug-resistant pathogens. This study evaluated in vitro antimicrobial activity of sulopenem by post-antibiotic effect (PAE), sub-inhibitory minimal inhibitory concentration PAE effect (PAE-SME), checkerboard testing, and time-kill testing. Testing sulopenem at 1×, 5×, or 10× the baseline MIC resulted in a PAE interval of 0.0–0.7 hours. When exposed to 0.5× the sulopenem MIC following 5× MIC, all isolate/agent combinations had PAE-SME values of >4.8 hours. Checkerboard testing revealed no instances of antagonism between sulopenem and comparator agents—indifference was observed in most sulopenem checkerboard combinations. Sulopenem demonstrated bactericidal activity (≥3 log 10 [99.9%] reduction in viable organism counts) in all time-kill assays following 24 hours of incubation at 8× the baseline MIC (6/6), 5/6 displaying this activity within 8 hours. The present antimicrobial parameters seen at concentrations surrounding the MIC support optimization of sulopenem dosing and further development. The oral dosing regimen of sulopenem etzadroxil/probenecid 500 mg/500 mg administered every 12 hours was recently evaluated in two phase 3 clinical trials where sulopenem demonstrated efficacy against amoxicillin-clavulanate in uncomplicated urinary tract infection (uUTI) and against ciprofloxacin in fluoroquinolone-resistant uUTI. IMPORTANCE Sulopenem is an oral and intravenous penem antibiotic in clinical development for treatment of urinary tract and intra-abdominal infections caused by multidrug-resistant pathogens. This study evaluated sulopenem via broth microdilution susceptibility testing, PAE, sub-inhibitory MIC PAE effect, checkerboard testing, and time-kill testing. The results of this study—interpreted along with recent pharmacodynamic in vitro one-compartment and hollow-fiber infection model work—provide insight into the in vitro activity of sulopenem.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Klebsiella pneumoniaeAnti-Bacterial AgentsEscherichia coliMicrobial Sensitivity TestsHumansDrug SynergismEscherichia coli InfectionsKlebsiella InfectionsMicrobial ViabilityUrinary Tract InfectionsDrug Resistance, Multiple, Bacterial

Stichwörter der Autor:innen

antimicrobial agentspost-antibiotic effectsusceptibility testingsynergismtime-kill curvesurinary tract infection

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • Element Iowa City-JMI Laboratories, North Liberty, Iowa, USA.
  • Iterum Therapeutics, Old Saybrook, Connecticut, USA.

ORCID-Profile: Joshua M Maher, Michael D Huband, Steven I Aronin, Mariana Castanheira

Zitieren

APA

Maher, J. M., Huband, M. D., Lindley, J. M., Rhomberg, P. R., Aronin, S. I., Puttagunta, S., & Castanheira, M. (2025). Characterization of sulopenem antimicrobial activity using in vitro time-kill kinetics, synergy, post-antibiotic effect, and sub-inhibitory MIC effect methods against Escherichia coli and Klebsiella pneumoniae isolates. Microbiology Spectrum. https://doi.org/10.1128/spectrum.01898-24

Vancouver

Maher JM, Huband MD, Lindley JM, Rhomberg PR, Aronin SI, Puttagunta S, et al. Characterization of sulopenem antimicrobial activity using in vitro time-kill kinetics, synergy, post-antibiotic effect, and sub-inhibitory MIC effect methods against Escherichia coli and Klebsiella pneumoniae isolates. Microbiology Spectrum. 2025. doi:10.1128/spectrum.01898-24

BibTeX
@article{Maher2025,
  author = {Maher, Joshua M and Huband, Michael D and Lindley, Jill M and Rhomberg, Paul R and Aronin, Steven I and Puttagunta, Sailaja and Castanheira, Mariana},
  title = {Characterization of sulopenem antimicrobial activity using in vitro time-kill kinetics, synergy, post-antibiotic effect, and sub-inhibitory MIC effect methods against Escherichia coli and Klebsiella pneumoniae isolates},
  journal = {Microbiology Spectrum},
  year = {2025},
  doi = {10.1128/spectrum.01898-24}
}
Kostenlos starten →